^
14d
Enrollment closed
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • LBL-007
22d
LBL-007-CN-004: A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors (clinicaltrials.gov)
P1/2, N=490, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
Trial completion date • Trial primary completion date • Combination therapy
|
cisplatin • gemcitabine • docetaxel • Tevimbra (tislelizumab-jsgr) • LBL-007
2ms
BGB-900-102: Study of BGB-A425 and LBL-007 in Combination with Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=358, Recruiting, BeiGene | Trial completion date: Dec 2027 --> Apr 2025 | Trial primary completion date: Mar 2026 --> Apr 2025
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • LBL-007 • surzebiclimab (BGB-A425)
2ms
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov)
P1, N=88, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Aug 2024 --> Mar 2025
Trial completion date • Trial primary completion date
|
Loqtorzi (toripalimab-tpzi) • Inlyta (axitinib) • LBL-007
3ms
Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors (clinicaltrials.gov)
P1/2, N=200, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Loqtorzi (toripalimab-tpzi) • LBL-007
4ms
Anti-LAG-3 Monoclonal Antibody Injection (LBL-007) Phase Ia Clinical Trial of Safety, Tolerance, Pharmacokinetics and Effectiveness in Patients with Advanced Solid Tumors and Advanced Lymphomas (ChiCTR1900025904)
P1, N=22, Completed, Cancer Hospital Chinese Academy of Medical Sciences; Leads Biolabs Co., Ltd. | Not yet recruiting --> Completed | N=36 --> 22
Trial completion • Enrollment change
|
LBL-007
6ms
Enrollment closed • Combination therapy • Metastases
|
cisplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • LBL-007
6ms
BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
P3, N=300, Enrolling by invitation, BeiGene | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
Trial completion date • Trial primary completion date • Metastases
|
temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • zanidatamab (ZW25) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • LBL-007 • surzebiclimab (BGB-A425)
10ms
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • BGB-15025 • BGB-A445 • LBL-007
11ms
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov)
P1, N=88, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Aug 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Loqtorzi (toripalimab-tpzi) • Inlyta (axitinib) • LBL-007
11ms
Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors (clinicaltrials.gov)
P1/2, N=200, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jul 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Loqtorzi (toripalimab-tpzi) • LBL-007
11ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • LBL-007 • surzebiclimab (BGB-A425)
11ms
Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • LBL-007
12ms
Phase classification
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
12ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
cisplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • LBL-007
1year
Enrollment open • Combination therapy • Metastases
|
cisplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • LBL-007
1year
Trial completion date • Trial primary completion date • Combination therapy • Mismatch repair • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
over1year
Enrollment open • Combination therapy • Mismatch repair • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
over1year
Enrollment open • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • LBL-007 • surzebiclimab (BGB-A425)
over1year
New P2 trial • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • LBL-007 • surzebiclimab (BGB-A425)
over1year
Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors (clinicaltrials.gov)
P1/2, N=200, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Dec 2023
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Loqtorzi (toripalimab-tpzi) • LBL-007
over1year
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov)
P1, N=88, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Aug 2023 --> Apr 2024 | Trial primary completion date: May 2023 --> Dec 2023
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
LAG3 (Lymphocyte Activating 3)
|
Loqtorzi (toripalimab-tpzi) • Inlyta (axitinib) • LBL-007
over1year
Enrollment closed • Combination therapy • Mismatch repair • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
over1year
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=200, Recruiting, BeiGene | Not yet recruiting --> Recruiting | N=300 --> 200 | Trial completion date: Nov 2025 --> Jul 2025 | Trial primary completion date: Nov 2025 --> Jul 2025
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • BGB-A445 • LBL-007
over1year
Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217) • LBL-007
almost2years
Trial initiation date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217) • LBL-007
almost2years
Enrollment open • Combination therapy • Mismatch repair • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
almost2years
Trial initiation date • Combination therapy • Mismatch repair • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Avzivi (bevacizumab-tnjn) • LBL-007
almost2years
New P2 trial • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • BGB-A445 • LBL-007
2years
New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217) • LBL-007
2years
BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=358, Recruiting, BeiGene | N=162 --> 358 | Trial completion date: Jan 2024 --> Dec 2027 | Trial primary completion date: Jul 2023 --> Mar 2026
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • LBL-007 • surzebiclimab (BGB-A425)
2years
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov)
P1, N=88, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Aug 2022 --> May 2023
Trial completion date • Trial primary completion date • Combination therapy
|
LAG3 (Lymphocyte Activating 3)
|
Loqtorzi (toripalimab-tpzi) • Inlyta (axitinib) • LBL-007
over3years
[VIRTUAL] Phase I study of LBL-007, a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody in patients with advanced solid tumors. (ASCO 2021)
The dose escalation part of the study revealed tolerability of LBL-007 with an impressive safety profile, and potentially some encouraging signs of anti-tumor activities . Clinical trial: Chinaclinicaltrials.org.cn (1900025904).
Clinical • P1 data
|
LAG3 (Lymphocyte Activating 3) • IL2 (Interleukin 2)
|
LBL-007